Amgen Inc. logo

Amgen Inc. (AMGN)

Market Closed
12 Jun, 20:00
BCBA BCBA
AR$
17,750. 00
+20
+0.1128%
AR$
1.74T Market Cap
19.61 P/E Ratio
0.07% Div Yield
547 Volume
18.58 Eps
AR$ 17,730
Previous Close
Add Transaction
Day Range
17,550 17,840
Year Range
10,625 19,280
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AMGN closed today higher at AR$17,750, an increase of 0.1128% from yesterday's close, completing a monthly increase of 2.5419% or AR$440. Over the past 12 months, AMGN stock gained 6.1603%.
AMGN is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on BCBA (ARS).

AMGN Chart

People also search for

PFE
Pfizer Inc.
AR$ 9,770
-0.1022%
LLY
Eli Lilly and Company CEDEAR
AR$ 30,340
-2.1921%

Amgen Inc. (AMGN) FAQ

What is the stock price today?

The current price is AR$17,750.00.

On which exchange is it traded?

Amgen Inc. is listed on BCBA.

What is its stock symbol?

The ticker symbol is AMGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.07%.

What is its market cap?

As of today, the market cap is 1.74T.

Has Amgen Inc. ever had a stock split?

No, there has never been a stock split.

Amgen Inc. Profile

Biotechnology Industry
Healthcare Sector
Robert A. Bradway CEO
BCBA Exchange
- ISIN
US Country
28,000 Employees
15 May 2026 Last Dividend
- Last Split
17 Jun 1983 IPO Date

Overview

Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.

Products and Services

  • Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
  • Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
  • Prolia - Addresses osteoporosis in postmenopausal women.
  • XGEVA - Prevents skeletal-related events.
  • Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
  • Nplate - Treats immune thrombocytopenia.
  • KYPROLIS - For relapsed or refractory multiple myeloma patients.
  • Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
  • EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
  • Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
  • BLINCYTO - For patients with acute lymphoblastic leukemia.
  • TEPEZZA - Treats thyroid eye disease.
  • KRYSTEXXA - Addresses chronic refractory gout.
  • Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.

Contact Information

Address: One Amgen Center Drive
Phone: 805 447 1000